NKTR Stock: Price, Earnings History and SEC Filings
Nektar Therapeutics (NKTR) last traded at $38.87, down 0.79% on the latest session and down 35.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.23 against an analyst estimate of $-2.06, a beat of 40.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NKTR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 13, 2026 | $-1.23 | $-2.06 | +40.29% |
| Mar 2026 | May 7, 2026 | $-1.82 | $-1.74 | -4.60% |
| Dec 2025 | Mar 12, 2026 | $-1.78 | $-2.76 | +35.51% |
| Sep 2025 | Nov 6, 2025 | $-1.85 | $-2.85 | +35.09% |
NKTR beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How NKTR reacts to earnings
Across its last 8 earnings releases, NKTR moved 3.0% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-13 | After close | -3.82% |
| 2026-05-07 | After close | -1.78% |
| 2026-03-12 | After close | +4.11% |
| 2025-11-06 | After close | +1.54% |
| 2025-08-07 | After close | +6.02% |
| 2025-05-08 | After close | -4.84% |
| 2025-03-12 | After close | +0.00% |
| 2024-11-07 | After close | +2.19% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
NKTR financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $55M | -$164M | -$209M | -297.1% | $-9.73 |
| 2024 | $98M | -$119M | -$177M | -120.9% | $-8.68 |
| 2023 | $90M | -$276M | -$193M | -306.3% | $-1.45 |
| 2022 | $92M | -$368M | -$310M | -400.0% | $-1.97 |
| 2021 | $102M | -$524M | -$428M | -514.0% | $-2.86 |
| 2020 | $153M | -$444M | -$321M | -290.6% | $-2.49 |
| 2019 | $115M | -$441M | -$355M | -384.5% | $-2.52 |
| 2018 | $1.2B | $681M | $704M | 57.1% | $3.78 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for NKTR
- 8-K · Oct 1, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Sep 25, 2026Other events
- 8-K · Sep 8, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 14, 2026
- 8-K · Aug 13, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 5, 2026Shareholder vote
- 424B5 · May 8, 2026
- 8-K · May 8, 2026Material agreement, Officer or director change, Financial statements and exhibits
- 10-Q · May 8, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
Insider filing activity
NKTR insiders filed 7 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
NKTR news
- Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?Oct 29, 2026 · finance.yahoo.com
- Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial MarketsOct 27, 2026 · finance.yahoo.com
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Oct 23, 2026 · finance.yahoo.com
About Nektar Therapeutics
Nektar Therapeutics (NKTR) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.